Xvivo Perfusion AB (publ) reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was SEK 154.57 million compared to SEK 94.29 million a year ago. Net income was SEK 6.89 million compared to SEK 7.53 million a year ago. Basic earnings per share from continuing operations was SEK 0.23 compared to SEK 0.26 a year ago. Diluted earnings per share from continuing operations was SEK 0.23 compared to SEK 0.26 a year ago.
For the six months, sales was SEK 295.19 million compared to SEK 186.94 million a year ago. Net income was SEK 21.06 million compared to SEK 12.3 million a year ago. Basic earnings per share from continuing operations was SEK 0.71 compared to SEK 0.42 a year ago. Diluted earnings per share from continuing operations was SEK 0.71 compared to SEK 0.42 a year ago.